Janux Therapeutics (JANX) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Janux Therapeutics (JANX) overview

Janux Therapeutics (JANX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 10.0m and operating profit of USD -158m; the year-end share price was 13.80 USD and market capitalisation was USD 833m. Janux Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Janux Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 957mFY 2025
Share price13.80 USDFY 2025 year end
RevenueUSD 10.0mFY 2025
Operating profitUSD -158mFY 2025
Net earningsUSD -114mFY 2025
Market capitalisationUSD 833mFY 2025 year end

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies using its TRACTr, TRACIr, and ARM platforms. Its pipeline includes T cell engagers and bispecific candidates under clinical investigation for cancer, including candidates targeting PSMA in prostate cancer and EGFR in solid tumors. The company also describes development of its ARM platform for autoimmune diseases and oncology.

Generate the Janux Therapeutics report

Janux Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Janux Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Janux Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.